Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity.
about
β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of CancerIntegrins Influence the Size and Dynamics of Signaling Microclusters in a Pyk2-dependent MannerGene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity.Quantitating ADCC against adherent cells: Impedance-based detection is superior to release, membrane permeability, or caspase activation assays in resolving antibody dose response.Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells
P2860
Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Integrin receptors on tumor ce ...... tibody-dependent cytotoxicity.
@en
Integrin receptors on tumor ce ...... tibody-dependent cytotoxicity.
@nl
type
label
Integrin receptors on tumor ce ...... tibody-dependent cytotoxicity.
@en
Integrin receptors on tumor ce ...... tibody-dependent cytotoxicity.
@nl
prefLabel
Integrin receptors on tumor ce ...... tibody-dependent cytotoxicity.
@en
Integrin receptors on tumor ce ...... tibody-dependent cytotoxicity.
@nl
P2093
P2860
P356
P1476
Integrin receptors on tumor ce ...... tibody-dependent cytotoxicity.
@en
P2093
Deborah J Marshall
Gordon D Powers
Kerry S Campbell
Maria Steblyanko
Nadia Anikeeva
Natalya Kopylova
Svetlana Fayngerts
Takami Sato
Yuri Sykulev
P2860
P304
P356
10.1002/EJI.201344179
P407
P577
2014-06-05T00:00:00Z